E
Power Law company profile
Eikon Therapeutics
Biotech & Life Sciences · Hayward, United States · Founded 2019 · IPO 2026 Unicorn
Valuation
$417M
Market cap · Apr/2026
Global footprint
Where Eikon Therapeutics has talent and traffic
AI talent share
2.2%
of workforce is AI talent
(9 of 404 staff)
(9 of 404 staff)
Core AI40.99%
Other AI51.24%
Non-AI workforce39597.77%
Web traffic by country
15K
monthly visits
across markets
across markets
🇺🇸 United States74.7%
🇬🇧 United Kingdom8.7%
🇵🇱 Poland6.7%
🇮🇳 India4%
🇩🇪 Germany4%
Patent intelligence
$35M patent portfolio · 56 active families
Total estimated portfolio value via Dealroom Patent Intelligence (Patsnap), with quality scores compared against same-sector peers.
Estimated portfolio value
$35M
8.4% of market cap · 5.5× the top peer Freenome ($6M)
56 active patent families
Where Eikon Therapeutics innovates
BioinformaticsComputational biologyDirect acyclic graphDirected acyclic graphComputer science
Above peer median on Legal · Below peer median on Strategic
Quality vs same-sector peers
Eikon Therapeutics on the five Patsnap quality dimensions
Eikon Therapeutics in orange. Same-sector peers are the top filers by total patent value. All scores 0–100; higher is stronger.
Compare against
Patent quality scores (0–100)
Source: Dealroom Patent Intelligence · PatsnapTech-focus vs peers
Where Eikon Therapeutics concentrates inside the peer cluster
Axes are the most-shared Patsnap topics across Eikon Therapeutics and its top peers. Each polygon's reach on an axis = how prominent that topic is in that company's portfolio (#1 topic = 100, #10 = 10, absent = 0).
Compare against
Top-topic prominence (rank inverted, 0–100)
Source: Dealroom Patent Intelligence · Patsnap top-10 topics per companySee Eikon Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.